Please login to the form below
PPMS
This page shows the latest PPMS news and features for those working in and with pharma, biotech and healthcare.
Roche shares new positive Ocrevus data for MS patients
The trial is a first-of-its-kind, open-label, phase 3b study evaluating the effect of Ocrevus in SPMS and PPMS patients. ... For 75% of patients diagnosed with SPMS and PPMS treated with Ocrevus, they showed no evidence of progression (NEP) after one year
Latest news
-
Roche’s Ocrevus shows significant benefit in early-stage MS patients
The post-hoc analysis of the ORATORIO study also showed that Ocrevus treatment slowed accumulation of atrophied T2-lesion volume (aT2-LV) compared with placebo at 120 weeks in PPMS. ... According to Roche, those living with PPMS experience three to five
-
Roche and NHS England hail pricing deal on MS drug Ocrevus
The agreement means NICE can now reverse the rejection it announced in November, and Ocrevus(ocrelizumab), will be fully available to patients with primary progressive multiple sclerosis (PPMS) in England, the ... England's contribution to its revenues
-
Dismay as NICE rejects Roche’s MS drug Ocrevus
and NICE to reach an agreement that will allow the drug to be covered for PPMS. ... We ask that NICE are given the flexibility to consider an indication-specific price for ocrelizumab in PPMS.”.
-
Daily Brief: Tecentriq set for breast cancer filing, Ocrevus gets NICE thumbs down, NHS needs more cash
NICE says no to Ocrevus in primary progressive MS. On Friday NICE announced that it would not recommend Roche; s Ocrevus (ocrelizumab) for treating primary progressive multiple sclerosis (PPMS) in adults. ... Ocrevus is the only drug approved for PPMS,
-
Roche’s Ocrevus is first primary progressive MS drug in EU
There are an estimated 96, 000 Europeans with PPMS, a highly-disabling early-onset form of the disease in which there is no relapsing/remitting stage. ... Nevertheless, the charity points out that the EU license means the drug can only be prescribed for
More from news
Approximately 2 fully matching, plus 8 partially matching documents found.
Latest from PMHub
-
It's time to change the conversation
Take Multiple Sclerosis (MS) for example. MS has four different disease manifestations: Relapsing Remitting (RRMS), Secondary Progressive (SPMS), Primary Progressive (PPMS) and Progressive Relapsing (PRMS).
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- NICE issues final draft recommending Novartis’ Scemblix to treat chronic myeloid leukaemia
- Alzheimer's Research UK supports government plans for clinical research
- GSK announces The HealthTree Foundation’s multiple myeloma programme as first ‘Think Tank’ challenge winner
- NRG Therapeutics partners with Domainex to develop neurodegenerative disease treatment
- Innovative Trials opens first US office
- Scanning for Health Indicators and Risks Through Your Smartphone
PMHub
Envision Pharma Group
We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...
Latest intelligence
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
